Skip to main content
. 2022 Feb 25;8:774623. doi: 10.3389/fmed.2021.774623

Figure 5.

Figure 5

Summary figure of the schematic workflow of the current study. (A) Initial screening of angiogenic factors and cytokines. (B) ELISA verification in validation cohort and related statistical analysis. (C) Involvement of TIMP-1 in the hPASMCs mechanism. COPD, Chronic obstructive pulmonary disease; COPD-PH, Chronic obstructive pulmonary disease associated pulmonary hypertension; CSE, Cigarette smoke exposure; ELISA, Enzyme-Linked Immunosorbent Assay; hPASMCs, Human Pulmonary Artery Smooth Muscle Cells; TIMP-1, Tissue Inhibitor of Metalloproteinases-1. This figure was created using BioRender.